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Abstract.  ICRF-193,  a novel noncleavable, complex- 
stabilizing type topoisomerase (topo) II inhibitor, has 
been shown to target topo II in mammalian cells 
(Ishida, R., T. Miki, T. Narita, R.  Yui,  S. Sato, 
K. R.  Utsumi, K.  Tanabe, and T. Andoh.  1991. Can- 
cer Res.  51:4909--4916).  With the aim of elucidating 
the roles of topo II in mammalian cells, we examined 
the effects of ICRF-193  on the transition through the S 
phase, when the genome is replicated, and through the 
M phase, when the replicated genome is condensed 
and segregated. Replication of the genome did not ap- 
pear to be affected by the drug because the scheduled 
synthesis of DNA and activation of cdc2 kinase fol- 
lowed by increase in mitotic index occurred normally, 
while VP-16, a cleavable, complex-stabilizing type 
topo II inhibitor, inhibited all these processes. In the 
M phase, however, late stages of chromosome conden- 
sation and segregation were clearly blocked by ICRF- 
193. Inhibition at the stage of compaction of 300-nm 
diameter chromatin fibers to 600-nm diameter chro- 
matids was demonstrated using the drug during 
premature chromosome condensation (PCC) induced 
in tsBN2 baby hamster kidney cells in early S and G2 
phases. In spite of interference with M phase chromo- 
some dynamics, other mitotic events such as activation 
of ode2 kinase, spindle apparatus reorganization and 
disassembly and re,  assembly of nuclear envelopes oc- 
curred, and the cells traversed an unusual M phase 
termed "absence of chromosome segregation" (ACS)-M 
phase. Cells then continued through further cell cycle 
rounds, becoming polyploid and losing viability. This 
effect of ICRF-193  on the cell cycle was shown to par- 
allel that of inactivation of topo II on the cell cycle of 
the ts top2  mutant yeast. The results strongly suggest 
that the essential roles of topo II are confined to the 
M phase, when the enzyme decatenates intertwined 
replicated chromosomes. In other phases of the cycle, 
including the S phase, topo II may thus play a com- 
plementary role with topo I in controlling the tor- 
sional strain accumulated in various genetic processes. 
topoisomerases (topo) t have been implicated  in 
e maintenance of genetic processes such as repli- 
ation, transcription, and recombination by control- 
ling the higher order chromosomal structure through the cell 
cycle (for review,  see Wang, 1985, 1987; Cozzarelli  and 
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nylidene)-~-D-glycopyranoside]. 
Wang, 1990; Vosberg, 1985). Topo I and II catalyze topolog- 
ical changes of DNA by transiently  introducing single- and 
double-strand breaks, respectively. While both topo I and II 
relax supercoiled DNA, topo II uniquely catalyzes knotting/ 
unknotting and catenation/decatenation.  In both Saccharo- 
myces cerevisiae and Schizosaccharomyces pombe,  species 
of yeast,  topo I, and topo II play complementary roles in 
controlling the topological  state of DNA during all the cell 
cycles, except metaphase, when topo II is essential for chro- 
mosome condensation and  segregation  (DiNardo  et  al., 
1984; Uemura and Yanagida, 1984, 1986; Uemura et al., 
1987; Holm et al.,  1985). 
In mammalian cells, however, the biological  function of 
topo II has not been as clearly identified as in yeasts because 
of the lack of topo II mutants. For this purpose, specific topo 
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methylepipodophyllotoxin-9-[4,6-(0-ethylidene)-/~-D-gly- 
copyranoside] (VP-16) and 4'-demethylepipodophyllotoxin- 
9-  [4,6-(0-thenylidene)-/~-D-glycopyranoside] (VM-26), have 
been applied to various biological systems. These agents in- 
duce DNA single- and double-strand breaks in mammalian 
cells via topo H-mediated cleavable complex formation.  The 
treated cells are arrested in G2 of the cell cycle, as generally 
observed for proliferating  eukaryotic cells exposed to a vari- 
ety of DNA damaging  agents (Krishan  et al.,  1975; Tobey, 
1975). The G2 arrest is brought about by a cellular mecha- 
nism ensuring  the order of cell cycle events, "check point 
control" (Hartwell and Weinert,  1989), which allows cells to 
repair damage before entering  mitosis.  The onset of mitosis 
is determined by activation of the master switch cdc2 protein 
kinase,  which requires dephosphorylation and association 
with B-type cyclin  (Nurse,  1990).  Treatment  of Chinese 
hamster cells in the G2 phase with an epipodophyllotoxin 
prevented their entering mitosis and also the cdc2 kinase ac- 
tivation,  suggesting that inhibition  of topo II through  cleav- 
able complex formation  somehow interferes  with the activa- 
tion of the cdc2 kinase and the entry into mitosis (Lock and 
Ross,  1990; Lock,  1992; Roberge et al.,  1990). 
Biochemical studies  in vitro with higher eukaryotic cells 
have suggested  the involvement  of topo II in condensation 
and segregation of chromosomes. Newport and Spann (1987) 
showed  that  in Xenopus mitotic extracts,  novobiocin,  and 
VM-26 prevented chromosome condensation.  Downes et al. 
(1991) showed that in mitotic HeLa or PtK2 cells, VP-16 in- 
hibited the segregation  of metaphase chromosomes. Shamu 
and Murray (1992) used an elegant Xenopus in vitro system, 
in which all the mitotic events take place synchronously and 
sequentially,  i.e., condensation and segregation  of chromo- 
somes followed by reassembly of nuclear envelope to form 
daughter  nuclei.  They demonstrated that  VM-26 inhibited 
the chromosome segregation.  While Sumner (1992) showed 
that  not all topo II inhibitors  block the passage of human 
lymphocytes through mitosis, the available data do lend sup- 
port to the hypothesis that topo II plays an important role in 
chromosome dynamics in mitosis.  However, this point re- 
mains controversial  because of the problem of determining 
whether the inhibition of chromosome dynamics by these in- 
hibitors  results from a specific inhibition  of topo II activity 
or a nonspecific  effect of the drug-induced protein-linked 
DNA cleavage. Thus the arrest of metaphase progression by 
these inhibitors  is in apparent conflict with observations in 
yeast,  where  inactivation  of  topo  II  activity  in  top2 
temperature-sensitive  (ts) mutants at a nonpermissive tem- 
perature does not result in cessation of cell cycle progres- 
sion,  but allows cells to traverse  mitosis, without chromo- 
some  segregation,  to  the  next  cell  cycle,  when  DNA is 
replicated  (Uemura and Yanagida,  1984,  1986; Uemura et 
al., 1987). It is relevant to refer here to the work done using 
cell-free extracts (Wood and Earnshaw,  1990; Adachi et al., 
1991;  Hirano  and  Mitchison,  1993),  which  obviated the 
complication caused by the use of drugs.  They showed that 
chromosome condensation was prevented by immunodeple- 
tion of topo II from the extract,  and the activity was restored 
by replenishment  of purified topo II. 
Bis(dioxopiperazines)  were originally  synthesized  as po- 
tential  intracellular  chelating  agents, and their biochemical 
and pharmacological  properties, including  antitumor  activ- 
ity, have been studied extensively over the past decades (for 
review, see Herman et al., 1982). The problem of inadequate 
bioavailability  limiting clinical  application  (Hellman et al., 
1969) has been approached by synthesis of various masked 
compounds showing improved bioavailability and higher an- 
titumor activity than the parental compound ICRF-154 (Cai 
et al.,  1989). MST-16, one of these compounds, has shown 
considerable therapeutic  activity against  a  number of ex- 
perimental tumors such as P388 and L1210 leukemias,  B-16 
melanoma, colon 26, etc. (Narita et al., 1990), and a cell cy- 
cle phase-specific mode of cytotoxicity (Narita et al., 1991), 
in  line  with  the  previous  demonstration  of toxic  action 
specific for G2/M (Sharpe et al., 1970). We have previously 
reported that  one of the potent derivatives  of ICRF-154, 
ICRF-193, inhibits topo II in such a manner that, unlike VP- 
16, it does not stabilize the cleavable complex (Tanabe et al., 
1991), but it does stabilize the enzyme in the form of a closed 
protein clamp by inhibiting  its ATPase  activity  (Roca and 
Wang, 1992; Roca et al., 1994). We also showed that ICRF- 
193 in fact targets topo II in vivo, as shown by competition 
with the DNA cleavage and cytotoxicity caused by VP-16 
(Ishida et al.,  1991). In the present study, we show that the 
compound exhibits  biological effects in  mammalian  cells 
analogous  to those observed in top2 ts mutants of yeast at 
nonpermissive temperature.  Thus,  in the presence of the 
drug, cells traverse many rounds of the cell cycle with their 
genome  replicated  but not  segregated,  resulting  in  poly- 
ploidization.  Other cell cycle events associated with transi- 
tion through  S phase and M phase take place normally. 
Materials and Methods 
Drugs 
The following drugs were girls from companies: ICRF-193, Zenyaku Kogyo 
Co. Ltd. (Tokyo); VP-16, Bristol Meyers-Squibb (Brea, CA); camptothecin 
(CPT), Yakult Honsha Co. Ltd. (Tokyo); neocarzinostatin, Kayaku Antibi- 
otics Research Co. Ltd. (Tokyo). The following drugs were purchased: TN- 
16 from Wako Pure Chemical Industries Ltd. (Osaka); 3,3'-dihexyloxacar- 
bocyanine iodide (DECC) from Kodak Laboratory Chemicals (Rochester, 
NY); coicemid from GIBCO BRL (Gaithersburg, MD). 
Cell Culture 
CHO strain AA8, HeLa  $3,  and tsBN2 cells were grown in Dulbecco's 
modified Eagle's medium containing  10% calf serum under a humidified 
atmosphere of 5% CO2 in air. tsBN2 cells, a temperature-sensitive mutant 
of  BHK21 cells, were cultured at 32.5°C (permissive temperature) or 41°C 
(nonpermissive temperature).  Cell numbers were counted with a Coulter 
counter  (Industrial  D;  Coulter  Electronics  Ltd.,  Luton  Bedfordshire, 
United Kingdom). For clonogenic assay, cells were treated with the drugs 
indicated in Fig. 8 for 30 min, washed with Tris-buffered saline two times, 
and suspended by trypsinization.  Cells were seeded at 3  x  102 cells/60- 
mm dish, cultured for 1 wk, fixed with 10% formalin in 0.9% NaC1, and 
stained with 0.1% crystal violet for counting colonies. Survival fractions of 
the drug-treated cells were expressed as percent of  control cells treated with 
solvent alone. 
Cell Synchronization 
Early S phase synchronization: HeLa $3 and CHO cells seeded at 1 ×  105 
cells/100-mm dish were cultured for 24 h in the presence of 1 mM thymi- 
dine, then for 9 h in the absence of thymidine, and then again for 16 h in 
the presence of  2 mM thymidine. Upon removal of  thymidine, cells traverse 
synchronously from early S phase to G2 phase, tsBN2 cells seeded on the 
previous day at  1  ×  105  cells/60-mm  dish were cultured  in isoleucine- 
deprived medium for 40 h, and transferred  to and cultured  in complete 
medium containing 2 mM hydroxyruea for 16 h. 
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k~nase  activation  and  progression  from  early  S 
phase  to  M  phase.  Cells  were  synchronized  in 
early S phase by double thymidine treatment as de- 
scribed in the  Materials and Methods.  After re- 
lease from the thymidine block,  HeLa cells were 
cultured in the absence (o) or presence of 5  ttM 
ICRF-193  (e) or  10 ~M VP-16 (A).  (,4)  Percent- 
ages  of mitotic cells  were  examined at the indi- 
cated times.  (B) Cdc2 kinase activities in control 
(o) and ICRF-193-treated (e) HeLa cells, deter- 
mined, as described in the Materials and Methods, 
using a  specific oligopeptide S1 of 13 amino acid 
residues,  which  is  the  recognition  sequence  for 
cdc2 kinase, as a  substrate (Yasuda et al.,  1990). 
(C)  Electrophoretic  mobility  of cdc2  kinase  in 
control (upper panel) and ICRF-193-treated cells 
(lower panel) at the indicated times, examined by 
immunoblot  analysis  using  polyclonal  antibody 
against an oligopeptide of the carboxy terminus of 
human  cdc2  kinase,  as  described  previously 
(Yasuda et al.,  1990).  (D) Cdc2 kinase activities 
in  control  (o)  and  5  #M  ICRF-193-treated  (e) 
CHO cells. (E) H1 kinase activities of control (up- 
per panel),  ICRF-193-  (middle panel), and VP- 
16- (lower panel) treated HeLa cells were deter- 
mined using histone H1  as a  substrate.  Reaction 
products  were  electrophoresed  on  SDS-PAGE, 
dried,  and subjected to autoradiography. 
G2 Phase Synchronization.  Isoleucine-starved tsBN2  cells,  as  de- 
scribed above, were transferred to and cultured  in complete medium con- 
taining 1 /~g/rnl neocarzinostatin for 16 h. 
M Phase Synchronization. HeLa and CHO cells were seeded at 2  × 
106 ceils/140-mm dish. On the next day, the medium was changed to fresh 
medium containing 0.5  mM  3-(1-anilinoethylidene)-5-benzylpyrrolidine- 
2,4-dione, an inhibitor of microtubule assembly (Hashimoto et al.,  1972). 
After 4-h incubation, round mitotic cells were collected from monolayer 
culture by selective mechanical detachment, as described by Terashima and 
Tolmach  (1963),  and washed with Tris-buffered  saline. 
Mitotic Figures 
Cell samples were suspended  in 1 ml of 75 mM KCI and stood at 0°C for 
20 min. 1 rnl of methanol-acetic  acid (3:1) was slowly added to the suspen- 
sion under constant mild agitation, and the cells were centrifuged down. 
After washing with 1 ml of the fixative, cells were resuspended in 30-100 
/zl of the fixative and dispensed onto glass slides. After drying, the samples 
were stained with Giemsa solution.  Mitotic cells and premature chromo- 
some condensation (PCC) cells were identified and counted under the mi- 
croscope. 
Immunofluorescence Microscopy 
Formalin-fixed cells were permeabilized with 0.5 % Triton X-100 in PBS for 
10 min and washed twice with PBS. For tubulin immunofluorescence,  cells 
were attached to poly-L-lysine-coated  coverslips  and then incubated with 
tubulin-specific  monoclonal antibody (Oncogene Science, Inc., Manhasset, 
NY) for 2 h at room temperature.  After washing three times with PBS, the 
samples  were  further incubated with FITC-conjugated  anti-mouse IgG 
(Kirkegaard  &  Perry Laboratories Inc., Gaithersburg, MD), and stained 
with 1 #g/ml Hoechst 33258  in PBS.  Coverslips  were  mounted in 50% 
glycerol  solution with 2.5%  1,4-diazabicyclo-[2,2,2]octane  as antibleach- 
ing agent.  For membrane staining, HeLa cells were fixed with methanol- 
acetic acid (3:1) as described above in the "Mitotic Figures" section. Fixed 
cells were stained with 1/~g/ml of DECC for 5 min, and washed with PBS. 
Assay of  cdc2 Kinase Activity and Its Immunoblotting 
Frozen cells were suspended  in hypotonic buffer (10 mM Tris-HC1, pH 7.4, 
3 mM MgCI2,  1 mM PMSF) at 0°C for 30 rain. Nonidet P-40 was added 
to a  final  concentration of 0.1%,  and the cells were  vortexed  and cen- 
trifuged.  The precipitate was washed twice with the hypotonic buffer with- 
out NP-40, then extracted with 0.4 M NaCI for 30 min, the resultant samples 
being centrifuged at 105,000 g for 1 h. The supernatant was used as a nu- 
clear fraction.  Cdc2 kinase activity was assayed using histone H1 or S1 pep- 
tides of 13 amino acid residues,  the specific recognition sequence of ode2 
kinase,  as a substrate by the method of Yasuda et al. (1990). For immuno- 
blotting, cell extracts were electrophoresed  in 12.5 % SDS-PAGE and trans- 
ferred to Immobilon membranes (Millipore Corp., Bedford,  MA). Filters 
were  blocked with 5%  skim milk and incubated with anti-cdc2 kinase 
(Yasuda et al., 1990). After washing with PBS, the filters were treated with 
125I-protein A. Dried filters were exposed  to x-ray film.  To determine H1 
histone phosphorylation, reaction products were electrophoresed in 12.5 % 
SDS-PAGE, and the gels were dried and subjected  to autoradiography. 
Results 
ICRF-193 Does Not Inhibit Transition of Cells  from 
S Phase to M Phase 
We have previously shown that when randomly growing cells 
are treated with ICRF-193,  the cells are not arrested in the 
G2 phase, but they appear to continue further through cell 
cycle and they become polyploid (Ishida et al.,  1991). This 
is unlike the inhibition observed with most other cleavable 
complex-stabilizing type topo II inhibitors. 
In the present study, we examined more closely the effect 
of ICRF-193  on cell cycle transition.  First, the transition 
from early S to M phases and the activation of cdc2 kinase 
were studied in HeLa and CHO cells synchronized in early 
S phase with a double thymidine block. After removal of the 
block, HeLa cells traversed through S, G2, and M phases 
during 12 h (Fig. 1 A; Ishida et al., 1991). Cdc2 kinase activ- 
ity increased gradually and peaked at 8 h slightly before the 
M phase (Fig. 1 B). The kinase activity is modulated by de- 
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Figure 2. ICRF-193 inhibition of cell division. Mitotic cells were 
collected as described in the Materials and Methods, plated in fresh 
medium containing ICRF-193, VP-16, or CPT, and the percentages 
of mitotic cells, judged by nuclear envelope formation (A and C), 
total cell number (B and D), and cdc2 kinase activity (E) were de- 
termined at the times indicated. HeLa (,4 and B) and CHO cells 
(C-E) were treated with 5 ~M ICRF-193 (e), 10O/~M VP-16 (A), 
10 #M CPT (a), or were left untreated (o). 
phosphorylation of the phosphorylated form, which can be 
detected by the mobility difference between the two forms on 
SDS  polyacrylamide  gel  electrophoresis  (Morla  et  al., 
1989).  As shown in Fig.  1, C and E, concomitant with in- 
crease in the kinase activity, dephosphorylation of the en- 
zyme increased. Addition of ICRF-193  in the early S phase 
delayed the progression of HeLa cells to M phase and the in- 
crease of the kinase activity (Fig. 1, A and B): total amount 
of p34  ~2  also  increased;  dephosphorylation thereof was 
delayed, and the phosphorylated form of the enzyme ap- 
peared to be maintained at a high level, even at 12 h after 
release from the thymidine block (Fig.  1, B, C and E). 
In  contrast,  the  epipodophyllotoxin VP-16 completely 
blocked the progression of cells to M phase and the increase 
in cdc2 kinase activity (Fig. 1, A and E), as reported earlier 
(Lock and Ross, 1990;  Lock, 1992;  Roberge et al., 1990). 
Unlike HeLa cells, a similar but undelayed rise in cdc2 ki- 
nase activity and transition to mitosis were observed in the 
drug-treated, synchronized CHO cells (Fig. 1 D), although 
the background activity level was high at 0 h after release 
from the double-thymidine block, due to poor synchroni- 
zation. 
ICRF-193 Inhibits Cell Division but Does not Affect 
the Traverse from M to (71 and S Phases 
Next,  we examined the effect of ICRF-193  on ceil cycle 
progression from M to G1 phases. Mitotic HeLa cells were 
collected using the microtubule inhibitor TN-16, and were 
released for traverse to the G1 phase in the presence of  ICRF- 
193. In control culture, mitotic cells exited from mitosis and 
progressed into the G1 phase within 2 h, as revealed by reas- 
sembly of the nuclear envelope, and the cell number almost 
doubled (Fig. 2, A and B). ICRF-193  delayed the exit from 
M phase by 2 h, and the cell division was inhibited (Fig. 2, 
A and B). At 5 h, all the cells were in interphase, although 
the cell number did not increase. Essentially the same results 
were  obtained  with  CHO  cells,  although  the  exit  from 
metaphase was faster and the rate was not affected by ICRF- 
193 (Fig. 2, C and D). The cdc2 kinase activity decreased 
as the cells exited from mitosis in the presence or absence 
of the drug (Fig. 2 E). 
Similar analyses were made to determine the effects of VP- 
16 and CPT, the latter being a cleavable, complex-stabilizing 
type topo  I  inhibitor on mitotic CHO  cells.  The results 
demonstrated that VP-16 inhibited cell division, as was the 
case with ICRF-193, whereas CPT affected neither exit from 
mitosis nor cell division (Fig. 2, C and D), confirming that 
topo II but not topo I is involved in chromosome segregation 
(Uemura and Yanagida,  1984,  1986;  Holm et al.,  1985). 
ICRF-193 Inhibits Segregation and Retards 
Decondensation of Chromosomes 
Since ICRF-193 inhibits cell division, but does not affect the 
exit  from  the  M  phase,  the  question  of how  the  drug 
influences the dynamic change of chromosomes and spindle 
formation in the M phase was addressed. As shown in Fig. 
3,  after release  from metaphase,  control untreated HeLa 
cells  underwent  mitosis  through  metaphase  (Fig.  3  D), 
anaphase,  and telophase (Fig.  3,  E-H),  and the chromo- 
somes were separated.  At 120 rain, most of the cells had 
progressed to G1 phase. In contrast, however, in the presence 
of ICRF-193,  cells in anaphase and telophase were seldom 
observed at any time after release from the M phase block 
(Fig, 3, J, L, and N), the result being consistent with the re- 
cent report of Clarke et al. (1993). Furthermore, the decon- 
densation of unsegregated chromosomes was delayed, as it 
was not complete at 180 rain, the cells having only slightly 
decondensed chromosomes like those of prophase,  rarely 
seen in control cells because of  the rapid progression through 
the phases. 
The Journal of Cell Biology,  Volume 126, 1994  1344 Figure 3. ICRF-193 inhibition of segregation and decondensation of chromosomes, but not spindle formation in mitotic HeLa cells. After 
removal of TN-16 as described in Fig. 2, cells were incubated in the presence (I-N) or in the absence (C-H) of 5/,M ICRF-193. At the 
indicated times, cells were fixed and stained sequentially with monoclonal antitubulin antibody (A, C, E, G, L K, and M), and Hoechst 
33258 (B, D, F, H, J, L, and N). 
Since the failure of chromosome segregation in the pres- 
ence of ICRF-193  may result from an inability to form spin- 
dles, we tested the effect of ICRF-193 on the formation of the 
spindle apparatus. After 20-60 min in the presence of the 
drug, spindles were formed and appeared to be connected 
with chromosomes (Fig. 3, I, K, and M). Thus, ICRF-193 
does not appear to affect spindle dynamics. 
ICRF-193 affected chromosome dynamics in CHO cells as 
in HeLa cells (Fig. 4),  progression through mitosis being 
much the same, but at a faster rate. It is of particular interest 
to note that in telophase, in the presence of  the drugs, spindle 
structures were transformed into midbodies at 40 rain, as in 
untreated cells (Fig. 4, E, F, K, and L, arrowheads), showing 
cytokinesis taking place. The chromosomes, however, were 
not separated and appeared  to be unequally separated to 
daughter cells (Fig. 4, K and L). 
ICRF-193 Does Not Block Nuclear 
Envelope Reassembly 
As described above,  cells enter an abnormal mitotic phase 
in the presence of ICRF-193.  In normal cells, concomitant 
with the entry into M phase, nuclear envelope breaks down 
and disappears, and then upon exit from mitosis, the nuclear 
envelope reassembles to form the nucleus. This is illustrated 
in Fig. 5, mitotic HeLa cells, after release from metaphase, 
progressing into G1 phase during 75 rain (Fig. 5, B, D, and 
F). Membrane vesicles first attach themselves to individual 
chromosomes and finally fuse to form the nuclear envelope 
(Fig. 5, A, C, and E). In the presence of ICRF-193,  decon- 
densation of chromosomes was delayed, and even after 120 
rain, the chromosomes did not completely decondense (Fig. 
5, H, J, and L). However, nuclear envelopes form around the 
periphery of fused chromosomes (Fig. 5,  G, 1, and K). 
ICRF-193 Does Not Inhibit Transition from Metaphase 
to the Next S Phase 
Cell cycle traverse from G1 to S phases was also examined 
by  [3H]thymidine  incorporation  monitoring  the  onset  of 
DNA synthesis. Mitotic CHO cells were plated in the pres- 
ence or absence of  ICRF-193, VP-16, and CPT, and they were 
allowed to proceed to (31 and S phases. DNA synthesis was 
initiated as scheduled in the presence of ICRF-193 and CPT, 
whereas it was not in the presence of  VP-16 (data not shown). 
Thus, the transition from G1 to S phases was not affected by 
ICRF-193 or CPT, but it was inhibited by VP-16. The results 
clearly show that ICRF-193 inhibits cell division but does not 
affect progression from M to G1 and further to the S phase, 
suggesting that topo I activity is sufficient for these transi- 
tions, and that topo H-mediated double-strand breakage in- 
duced by VP-16 blocks entry into the S phase. 
ICRF-193 Partially Inhibits Premature Chromosome 
Condensation in S and G2 Phases 
In a previous paper (Ishida et al., 1991) we documented that 
Ishida et al. ICRF-193 Uncouples Chromosome Dynamics from Cell Cycle  1345 Figure 4. ICRF-193 inhibition  of segregation  of chromosomes in mitotic CHO cells.  Mitotic cells collected as described in the Materials 
and Methods were incubated  in the presence (G-L) or in the absence (A-F) of 5/~M ICRF-193. At the indicated  time points,  cells were 
fixed and stained  with monoclonal antitubulin  antibody (A, C, E, G, L  and K) and Hoechst 33258 (B, D, F, H, J, and L). 
when  RPMI8402  leukemic  cells  were  treated  with  ICRF- 
193, the mitotic index did not increase, but abnormal mitotic 
figures were observed, e.g., early prophase-like figures and 
clumps of long entangled chromatid fibrils. It was suggested 
that  the  drug  inhibits  chromosome condensation  at  some 
early stage. 
To confirm this, we turned to the tsBN2 mutant of BHK21 
ceils,  which  exhibit  PCC  at  a  nonpermissive  temperature 
(Nishimoto et al.,  1978). PCC mimics normal chromosome 
condensation, as evidenced by the activation of cdc2 kinase 
and  association  of mitosis-specific  antigen  recognized  by 
monoclonal  antibody  MPM-2  with  PCC  chromosomes 
Figure 5.  ICRF-193  does not 
block  reassembly  of nuclear 
envelopes. Mitotic HeLa cells 
were cultured  in the presence 
(G-L) or in the absence (A-F) 
of  5  ttM  ICRF-193,  as  de- 
scribed for Fig. 3. At the indi- 
cated times, cells were double 
stained  with  the  membrane- 
specific stain DECC (A, C, E, 
G, I, and K) and with Hoechst 
33258 (B, D, F, H, J, and L). 
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tsBN2  cells  treated  with 
ICRF-193.  Cells  were  syn- 
chronized at early S phase by 
isoleucine  deprivation  fol- 
lowed by 2 mM hydroxyurea 
treatment (Nishimoto et  al., 
1981). Cells were  shifted  up 
to 41°C for 2 h in the presence 
of  hydroxyurea.  S-PCC 
preparations  obtained  from 
control (A and B) and ICRF- 
193-treated  cells  (C and D) 
were examined under the mi- 
croscope  and  photographed. 
Bars,  5 #m. 
Figure  7.  G2-PCC figures  in 
tsBN2  cells  treated  with 
ICRF-193.  tsBN2  cells  were 
synchronized  at G2 phase  by 
isoleucine  deprivation  fol- 
lowed  by  neocarzinostatin 
treatment as described previ- 
ously  (Ishida  et  al.,  1985). 
Cells were shifted up to 41°C 
for  2  h  in  the  presence  of 
neocarcinostatin. Control (A 
and  B)  and  10  ttM  ICRF- 
193-treated cells were exam- 
ined for PCC. Bar, 5 #m; the 
magnification of all panels is 
the same. 
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Figure 8. 1CRF-193 kills mitotic cells. Mitotic CHO cells collected 
as described in the Materials and Methods were cultured in fresh 
medium. At the times indicated, aliquots were treated for 30 min 
with 2 #M (e) or 10 #M (o) ICRF-193, or 3 #M CPT (A), washed 
with PBS, and plated for colony formation. 
(Nishitani et al.,  1991).  To establish whether ICRF-193 in- 
hibits the PCC in S or G2 phases, tsBN2 cells were first syn- 
chronized in early S  phase by isoleucine deprivation fol- 
lowed by hydroxyurea treatment. Upon a temperature shift 
up to 41°C, PCC was induced after a lag of 1 h and reached 
20% at 2 h and 32% at 4 h (data not shown). ICRF-193 did 
not appear to affect the induction of PCC.  However, PCC 
figures considerably  differed from those  of normal  PCC 
(Figs. 6 and 7). S-PCC figures comprised two distinct types 
of dot: highly condensed round or oval dots with a diameter 
of,'~600 nm, and smaller and less dense dots with a diameter 
of 100-300 nm (Fig. 6, A and B). The dense dots increased 
and the light dots decreased as the cells progressed along the 
S phase, suggesting that the former are replicated chromatin 
segments and the latter are unreplicated segments.  In the 
presence of ICRF-193, the chromosomes corresponding to 
the larger condensed dots became stretched with reduction 
of width to 300 um while the other PCC dots were not appar- 
ently changed (Fig. 6,  C and D). 
We have also examined the effect  of  ICRF-193 on induction 
of G2-PCC, using cells synchronized in the G2 phase by neo- 
carzinostatin (Ebina et al.,  1975; Ishida et al.,  1985) after 
isoleucine deprivation. ICRF-193 again did not inhibit the in- 
duction  of PCC  itself.  G2-PCC  figures  of control  cells 
resembled those of normal mitotic cells (Fig. 7, A and B), 
whereas PCC figures of ICRF-193-treated cells were quite 
different and bizarrely shaped,  i.e.,  much less condensed 
chromatids were highly entangled (Fig. 7,  C and D).  The 
same figures were earlier observed in  randomly growing 
cells treated with the drug (Ishida et al., 1991). These obser- 
vations clearly show that ICRF-193 does not inhibit entry 
into mitosis, but it does interfere with chromosome conden- 
sation toward the final step(s),  i.e., resolution of the con- 
densing chromatids followed by compaction thereof. In con- 
trast  to  these  observations,  however,  VP-16  at  100  #M 
inhibited entry into S-PCC by 90%, but CPT at an equitoxic 
dose of 2 #M had only marginal effects (data not shown). 
ICRF-193 Kills Cells Most Effectively at Metaphase 
Finally, we examined the effects of ICRF-193 on cell sur- 
vival. Metaphase-synchronized CHO cells were treated with 
ICRF-193 or camptothecin as a control for 30 rain at 2-h in- 
tervals, and were plated for survival by colony formation. As 
shown in Fig. 8, cells appeared to be most sensitive to ICRF- 
193 in metaphase and least sensitive in the S phase, whereas 
cells were least sensitive to camptothecin in metaphase and 
most sensitive in the S phase, as previously described (Li et 
al.,  1972; Horwitz et al.,  1973). 
Discussion 
Investigation of the roles of topo II in higher eukaryotes has 
been hampered by the lack of established mutants. In lower 
eukaryote yeast, however, studies using single top2 and dou- 
ble topltop2 mutants  (DiNardo et al.,  1984;  Uemura and 
Yanagida,  1985,  1986;  Uemura et al.,  1987;  Holm et al., 
1985) have revealed a major role of topo II in the resolution 
of catenated replicated daughter DNAs, facilitating both the 
condensation and segregation of chromosomes. Thus, single 
top2 mutants were found to show cell cycle-dependent  arrest 
at metaphase at the nonpermissive temperature:nuclear di- 
vision did not take place normally, but the cell plate was 
formed, cutting across the nucleus, presenting a "cut" pheno- 
type. When the top2 mutant was combined with a septum- 
defective, cold-sensitive mutation,  cdcll,  large cells with 
single nuclei containing several-fold higher levels of DNA, 
RNA,  and protein accumulated at the nonpermissive tem- 
perature, strongly suggesting that the mutant cells traverse 
many rounds of cell cycle with their genome replicated but 
unsegregated (Uemura et al.,  1987). The function of topo I 
is considered to be the maintenance of chromatin organiza- 
tion throughout the cell cycle, i.e., continuous removal of 
torsional  strain  accumulating  in  DNA  molecules  during 
genetic processes such as replication and transcription, and 
defects in topo I can be complemented with topo H. These 
observations point to the essential role of topo II in the cell 
cycle being the decatenation and/or unknotting of the cate- 
nated DNA necessary for chromosome dynamics in mitosis; 
upon inactivation of the enzyme, however, all the other cellu- 
lar processes associated with cell cycle transition proceed 
normally, resulting in the accumulation of polyploid cells. 
Induction of Polyploidy by ICRF-193 
In a previous paper, we showed that cells accumulate with 
a high DNA content, multilobed nuclei, and abnormal mi- 
totic figures in the presence of ICRF-193 (Ishida et al., 1991, 
1993; Andoh et al., 1993). In the present study, examination 
of how  ICRF-193  induces polyploidy using  synchronized 
cells demonstrated unusual mitoses with entry into G1 with- 
out cell divison, and continuation to S phase replication of 
DNA, resulting in the accumulation of cells with high DNA 
content and multilobed nuclei. Cells in mitosis have less con- 
densed chromosomes that appear to be similar to those in 
prophase.  These chromosomes were unable to segregate, 
and thus cells in anaphase and telophase were not observed. 
From these results, we propose a model for the influence 
of ICRF-193 on cell cycle progression. In the presence of 
ICRF-193, cells continue to traverse the cell cycle and go 
through an unusual M phase, which we tentatively name the 
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this ACS-M phase, late stage chromosome condensation and 
its segregation are inhibited, but decondensation of chromo- 
somes does occur at reduced rates. Other mitotic events such 
as disassembly and assembly of nuclear envelopes, spindle 
formation,  and cytokinesis,  etc.,  triggered by activation of 
cdc2 kinase, proceed almost normally in CHO cells and are 
slightly delayed in HeLa cells. Thus, the other mitotic events 
are uncoupled  from chromosome  dynamics.  These results 
differ in part from those obtained with the epipodophyllotox- 
ins VP-16 or VM-26, where cell cycle progression was found 
to be inhibited and cells were arrested in G2 (Tobey et al., 
1975; Krishan et al., 1975; Roberge et al., 1990). Since VP- 
16 and VM-26 cause DNA strand breaks in vivo as protein- 
concealed breakage or cleavable complexes (D~,rpa and Liu, 
1989; Liu, 1989), G2 arrest is thought to be brought about 
by these rather than by inhibition of topo II activity per se 
(Lock and Ross, 1990; Lock, 1992). Our present observa- 
tion that cells can traverse the cell cycle without cell division 
does not correlate with the effect of VP-16, but it agrees es- 
sentially with the behavior of top2 ts mutants of  yeast at non- 
permissive temperature.  This suggests that the functions of 
mammalian and yeast topo II in the cell cycle are essentially 
the same. 
Polyploidlzation has been shown to be induced by various 
agents  such  as  trichostatins  (Yoshida and Beppu,  1988), 
K-252a, a staurosporine  derivative (Usui et al., 1991), and 
spindle assembly inhibitors  (Kung et al.,  1990). However, 
unlike ICRF-193, trichostatins and K-252a, inhibitors of  his- 
tone deacetylase  and protein  kinases,  respectively, induce 
polyploidy,  not by passage through mitosis,  but rather by 
causing  traverse  from G2  directly  to G1  without  nuclear 
envelope  breakdown.  In  the  presence  of  inhibitors  of 
microtubule  assembly  such  as  colcemid  and nocodazole, 
CHO but not HeLa ceils traverse into the next cell cycle 
without cell division (Kung et ai., 1990). Even topoisomer- 
ase II inhibitors  such as VM-26 and 4-(9-acridlnylamino)- 
methanesulfon-m-anisidide (m-AMSA) were found to induce 
polyploidization  under certain conditions  (Zucker  et al., 
1991). Thus, the induction of polyploidy by chemical agents 
is a widely observed phenomenon, but it differs mechanisti- 
cally according to the drug and cell line. ICRF-193 is ap- 
parently unique in induction of polyploidy by allowing cells 
to traverse  from a  mitotic,  prophase-like  state  to the G1 
phase through the ACS-M phase. 
Topoisomerase H is Required  for Chromosome 
Condensation at a Late Stage, and  for Segregation 
at Anaphase 
Topoisomerase II is localized  in interphase  nuclei and on 
metaphase chromosomes (Berrios et al., 1985; Earnshaw et 
al., 1985; Earnshaw and Heck,  1985; Gasser et al., 1986). 
In budding  and fission yeasts,  temperature-sensitive  top2 
mutants have demonstrated that topo II is required for full 
condensation  of chromosomes,  as  well as  for the proper 
segregation of sister chromatids at mitosis (DiNardo et al., 
1984; Uemura  and Yanagida, 1986; Uemura et al.,  1987; 
Holm et al.,  1989). In higher eukaryotes, the enzyme has 
also  been  implicated  in  chromosome  condensation  and 
segregation (Earnshaw,  1988; Wood and Earnshaw,  1990; 
Wright and Schatten,  1990; Roberge et al., 1990; Adachi et 
al., 1991; Hirano and Mitchison,  1991; Downes et al., 1991; 
Shamu and Murray, 1992; Sumner, 1992; Bucbenau et al., 
1993). However, this point remains controversial,  because 
many studies have used topoisomerase  II inhibitors  such 
as the epipodophyllotoxins  VP-16 and VM-26, as well as 
m-AMSA,  which  stabilize  enzyme-mediated  cleavage of 
DNA, which itself  may cause the arrest of  chromosome con- 
densation and segregation. 
The problem was obviated, however, by approaches using 
immunological depletion of topo II from nuclear extracts, 
whereby  chromosome  condensation  was  prevented,  and 
replenishment of  the enzyme  restored the activity (Wood and 
Earnshaw, 1990; Adachi et al., 1991; Hirano and Mitchison, 
1993). In the present study, we applied the specific topo II 
inhibitor  ICRF-193 to establish  the role of the enzyme in 
chromosome dynamics,  tsBN2 cells, when shifted up to a 
nonpermissive  temperature,  undergo  PCC  synchronously, 
associated with a series of  mitotic events including activation 
of  cdc2 kinase, and association of  MPM-2 antigen with chro- 
mosomes (Nishitani et al.,  1991). ICRF-193 added to this 
system did not inhibit PCC in S phase or G2 phase, but in- 
terestingly appeared to prevent the final stage of condensa- 
tion,  i.e., compaction  of 300-nm fibrils to 600-nm  chro- 
matids (Figs. 6 and 7). In S-PCC, 300-nm fibrils of various 
lengths appeared, and in G2-PCC, more extensively tangled 
300-nm fibrils were observed in the presence of the drug. 
However, how this step of folding is brought about remains 
unclear. 
Uemura et al. (1987) elegantly demonstrated that topo II 
is required for chromosome segregation in anaphase using 
the double mutant tstop2-csnda3, in which spindle formation 
is cold sensitive. Our experimental conditions are in princi- 
ple the same as for the yeast mutant: cells were arrested in 
metaphase by the microtubule inhibitor TN-16 (correspond- 
ing to cold-sensitive nda3 at 20°C),  followed by inhibition 
of topo II activity by ICRF-193 (corresponding to ts top2 at 
36°C). The results shown in Figs. 2-4 clearly demonstrate 
that mammalian topo II is also required  for chromosome 
segregation.  Clarke et al.  (1993) recently reported  similar 
ICRF-193 inhibition  of chromosome  segregation in HeLa 
and PtK2 rat kangaroo cells.  However, in their study, they 
failed to observe any inhibition of chromosome condensa- 
tion. This difference may have stemmed from the difference 
in the mode of treatment:  they treated  randomly growing 
cells for a short period of time, whereas we treated tsBN2 
cells long enough before reaching PCC for topo II to become 
fully inactivated. Chen and Beck (1993) made a similar ob- 
servation of inhibition of chromosome condensation and in- 
duction of polyploidization of human leukemic CEM/VM-1 
cells exposed to merbarone,  a noncleavable complex stabi- 
lizing type topo II inhibitor. 
Extensive Catenation of the Genome Escapes 
Checkpoint Controls 
In eukaryotic cells, the initiation of mitosis is dependent on 
the completion of S phase, and this dependence is ensured 
by a surveillance mechanism,  termed a checkpoint control 
(Hartwell  and Weinert,  1989; Enoch  and Nurse,  1990), 
which inhibits entry into the M phase until replication or the 
repair of  damage to DNA has been completed. Premature M 
phase entry without completion of replication or repair of 
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in fission yeast (Hartwell and Weinert,  1989) and tsBN2 of 
baby hamster BHK21 cells (Nishimoto et al., 1978). Activa- 
tion of cdc2 kinase by dephosphorylation has been found to 
play  an  important  role  in  coupling  the  M  and  S  phases 
(Nurse,  1990;  Smythe and Newport,  1992). 
A consistent finding is that cdc2 kinase is not activated  in 
the presence of the epipodophyllotoxin VP-16, and cells were 
arrested  in G2 phase (Lock and Ross,  1990;  Lock,  1992; 
Roberge et al., 1990). In contrast, checkpoint control is not 
turned on, even if topoisomerase H function is inhibited by 
ICRF-193.  However, the effects of ICRF-193  on activation  of 
cdc2 kinase and on cell cycle transition  differed slightly be- 
tween the two cell lines HeLa and CHO, with delay of kinase 
increase only occurring in the former. The delayed activation 
of the kinase observed in HeLa cells appeared  to parallel 
delayed  dephosphorylation  of p34  ~2  and a  significant in- 
crease in the total amount of p34  ~2 (Fig.  1 C). This anom- 
alous pattern may be ascribed to a behavior of cyclin B, a 
partner and the activator of p34  ~°2. Steinmann et al. (1991) 
reported that okadaic acid, a protein phosphatase inhibitor, 
induces  premature  chromosome  condensation  in  rodent 
ceils, but not in HeLa cells in S phase,  with this cell-type 
specific difference being ascribed to the much increased ac- 
cumulation of cyclin B only in the rodent case. Kung et al. 
(1990) showed that spindle assembly is more stringently  cou- 
pled with certain karyokinetic  events  in HeLa than  CHO 
cells  in terms  of cdc2  kinase activation  by cyclin B.  The 
difference in the response to ICRF-193  of the two cell lines 
used in the present study  may thus  be a reflection of this 
difference in cyclin B metabolism. 
We recently reported that ICRF-193  does not inhibit chain 
elongation during SV-40 DNA replication in vitro, but that 
it  blocks  decatenation  of  replicated  daughter  molecules 
(Ishimi  et  al.,  1992).  If  this  same  situation  prevails  in 
genomic DNA in vivo, it would appear that in the presence 
of ICRF-193,  the extensively catenated genome escapes the 
cellular surveillance mechanism because the cells proceed to 
M phase. However, as we show in Fig. 8, entry into mitosis 
without active topo II is lethal,  even though the cells are 
capable of traversing  further  rounds of G1 and S phases. 
In conclusion, using a novel topo II inhibitor,  ICRF-193, 
which inhibits only catalytic activity without forming cleav- 
able complex, we could show that topo II plays an essential 
role as a decatenase in the resolution of replicated chromatin 
and of chromosomes in G2 and M phases. In other phases 
of the cell cycle, the enzyme may play a role complementary 
to topo I in transcription  and replication.  Of great interest 
is the fact that inactivation of the enzyme by the drug uncou- 
ples  chromosome  dynamics  from the  other  cellular  pro- 
cesses of the cell cycle, which normally proceed in coordi- 
nation. 
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